NADAC acquisition cost data for HUMIRA PEN PSORIASIS-UVEITIS-ADOL HS STARTER 40 MG/0.8 ML. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00074433907 | $3,115.30 | 2022-01-14 | Rx |
| 00074433907 | $3,115.30 | 2022-01-14 | Rx |
| 00074433907 | $3,115.30 | 2022-01-14 | Rx |
| 00074433907 | $3,115.30 | 2022-01-14 | Rx |
| 00074433907 | $3,115.30 | 2022-01-14 | Rx |
| 00074433907 | $3,115.30 | 2022-01-14 | Rx |
| 00074433907 | $3,115.30 | 2022-01-14 | Rx |
| 00074433907 | $3,115.30 | 2022-01-14 | Rx |
| 00074433907 | $3,115.30 | 2022-01-14 | Rx |
| 00074433907 | $3,115.30 | 2022-01-14 | Rx |
Generic: Adalimumab | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $484.9M | 74,567 | 11,858 | $2,601.24 |
| 2020 | $383.6M | 54,896 | 8,312 | $2,777.58 |
| 2021 | $328.6M | 44,560 | 6,530 | $2,986.81 |
| 2022 | $298.0M | 38,494 | 5,598 | $3,204.18 |
| 2023 | $257.6M | 30,607 | 4,742 | $3,568.20 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $28.8M | 3,651 | 733 |
| New York | $19.0M | 2,092 | 355 |
| Texas | $15.5M | 1,866 | 291 |
| Michigan | $15.3M | 1,870 | 261 |
| Florida | $14.7M | 1,845 | 287 |
| Pennsylvania | $11.1M | 1,332 | 190 |
| Massachusetts | $9.8M | 1,112 | 153 |
| Ohio | $8.7M | 1,019 | 156 |
| North Carolina | $8.6M | 952 | 147 |
| Illinois | $8.1M | 927 | 139 |
| Kentucky | $8.0M | 901 | 130 |
| Washington | $6.8M | 814 | 129 |
| New Jersey | $6.3M | 722 | 116 |
| Georgia | $6.1M | 738 | 123 |
| Tennessee | $5.7M | 705 | 96 |
| Minnesota | $5.4M | 624 | 86 |
| South Carolina | $4.9M | 488 | 84 |
| Louisiana | $4.6M | 546 | 75 |
| Wisconsin | $4.6M | 557 | 77 |
| Arizona | $4.5M | 574 | 102 |
| Missouri | $4.5M | 536 | 79 |
| Colorado | $4.1M | 476 | 95 |
| Virginia | $4.1M | 453 | 79 |
| Indiana | $4.0M | 425 | 69 |
| New Mexico | $3.5M | 484 | 78 |
| Connecticut | $3.4M | 384 | 57 |
| Mississippi | $3.4M | 443 | 63 |
| Oklahoma | $3.3M | 385 | 54 |
| Alabama | $2.6M | 341 | 56 |
| Maryland | $2.5M | 317 | 65 |
| Oregon | $2.1M | 255 | 47 |
| Puerto Rico | $2.0M | 284 | 36 |
| Maine | $2.0M | 218 | 32 |
| Arkansas | $1.9M | 238 | 42 |
| West Virginia | $1.8M | 227 | 39 |
| Iowa | $1.8M | 225 | 38 |
| Nevada | $1.7M | 200 | 37 |
| Kansas | $1.4M | 161 | 27 |
| Alaska | $1.3M | 117 | 20 |
| New Hampshire | $1.2M | 122 | 23 |
| Nebraska | $1.0M | 125 | 15 |
| Utah | $968.5K | 108 | 19 |
| Delaware | $944.8K | 119 | 16 |
| Montana | $808.1K | 97 | 21 |
| Rhode Island | $747.1K | 92 | 12 |
| Idaho | $714.4K | 91 | 18 |
| Hawaii | $700.2K | 84 | 12 |
| District of Columbia | $606.9K | 72 | 12 |
| Wyoming | $564.0K | 68 | 11 |
| South Dakota | $557.1K | 62 | N/A |
| North Dakota | $459.6K | 51 | N/A |
| Vermont | $157.6K | 12 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.